Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 5:14:415-434.
doi: 10.2147/IDR.S287792. eCollection 2021.

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study

Ilinca A Dutescu  1 , Sean A Hillier  1
Affiliations
Review

Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study

Ilinca A Dutescu et al. Infect Drug Resist. .

Abstract

Antibiotic resistance is an urgent public health threat that has received substantial attention from the world's leading health agencies and national governmental bodies alike. However, despite increasing rates of antibiotic resistance, pharmaceutical companies are reluctant to develop new antibiotics due to scientific, regulatory, and financial barriers. Nonetheless, only a handful of countries have addressed this by implementing or proposing financial incentive models to promote antibiotic innovation. This study is comprised of a systematic review that aimed to understand which antibiotic incentive strategies are most recommended within the literature and subsequently analyzed these incentives to determine which are most likely to sustainably revitalize the antibiotic pipeline. Through a case study of Canada, we apply our incentive analysis to the Canadian landscape to provide decision-makers with a possible path forward. Based on our findings, we propose that Canada support the ongoing efforts of other countries by implementing a fully delinked subscription-based market entry reward. This paper seeks to spark action in Canada by shifting the national paradigm to one where antibiotic research and development is prioritized as a key element to addressing antibiotic resistance.

Keywords: Canada; antibiotics; antimicrobial resistance; financial incentives; health policy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study flowchart according to the PRISMA recommendations.Notes: PRISMA figure adapted from Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10). Creative Commons.33
See this image and copyright information in PMC

References

    1. Sinha MS, Kesselheim AS. Regulatory incentives for antibiotic drug development: a review of recent proposals. Bioorg Med Chem. 2016;24(24):6446–6451. doi:10.1016/j.bmc.2016.08.033 - DOI - PubMed
    1. Office of National Statistics. Causes of death over 100 years. 2017. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarri.... Accessed April10, 2020.
    1. Jones DS, Podolsky SH, Greene JA. The burden of disease and the changing task of medicine. N Engl J Med. 2012;366(25):2333–2338. doi:10.1056/NEJMp1113569 - DOI - PubMed
    1. Podolsky SH. The evolving response to antibiotic resistance (1945–2018). Palgrave Commun. 2018;4:1. doi:10.1057/s41599-018-0181-x - DOI
    1. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658. doi:10.2147/IDR.S173867 - DOI - PMC - PubMed

LinkOut - more resources